Intervet Inc.

Intervet International B.v.

Jason Erskine

Mohamad A Morsey

Ian Tarpey

Yuanzheng Zhang

Denise Bartels-Morozov

Leonard G Presta

Leonard Presta

Denise Bartels - Morozov

Mohamad Morsey

The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.

Antibodies against canine PD-1

The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.

PD-L1 antibodies binding canine PD-L1

The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.

Caninized murine antibodies to human PD-1

The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.

Growing community of inventors

Omaha, NE, United States of America

Jason Erskine